Skip to content
MaaT Pharma

microbiota gut

  • About us
    • Key figures
    • Our vision
    • Governance
    • Our CSR objectives
    • Membership
  • Platform
    • Microbiome Ecosystem Therapies
    • MET-N
    • MET-C
    • gutPrint®
    • cGMP manufacturing facility
  • Pipeline
    • Overview
    • Xervyteg®
    • MaaT033
    • MaaT034
    • MaaT03X
    • Scientific Publications
  • Patients & HCPs
    • Healthcare professionals (HCPs)
    • Hemato-Oncology
    • Immuno-Oncology
    • Frequently Asked Questions
  • News
    • Corporate profile
    • Press Releases
    • Media Coverage
    • Posters
    • Videos
  • Investors
    • Stock information
    • Events & Presentations
    • Regulated information
    • Shareholders Meetings
    • CSR
  • Careers
    • Our values
    • Meet our people
  • French

Tag: Actionnariat

April 4, 2025: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General Regulations of the Financial Markets Authority (AMF - Autorité des Marchés Financiers) Lyon, France, April 4th, 2025 - 6:00pm CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader [...]
  • English
  • Français (French)